Innovative Technology Development for Cancer Research (R21)

archived

Purpose. This Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications proposing technically innovative feasibility studies focused on early stage development of cancer-relevant technologies. If successful, these technologies would accelerate the research and understanding of basic cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. This FOA solicits R21 applications and is suitable for projects at their inception, conceptual or idea based, where technical feasibility of the proposed technology or methodology has not yet been established. The R21 mechanism requires high potential impact and allows for an element of technical risk; projects proposed in response to this FOA may reflect this level of risk but must have concurrent potential to produce a major impact in a broad area of cancer-relevant research. All projects must include quantitative milestones (i.e. technical metrics that determine whether the specific aims have been accomplished). Projects proposing to use technology that is already established or projects where the novelty resides in the biological or clinical question being pursued are examples of topics not appropriate for this solicitation and will be returned as non-responsive. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Mechanism of Support. This FOA will utilize the NIH Exploratory/Developmental (R21) grant mechanism. Funds Available and Anticipated Number of Awards. The NCI intends to commit a total of approximately $5,000,000 to this FOA in fiscal year 2010 to fund up to 15 applications in response to this FOA.

High